Study guide

9.2 Safe Handling, Administration, and Vesicant Precautions

Certified Pediatric Hematology Oncology Nurse CPHON®

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy

2 Care Continuum

2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship

3 Leukemias and Lymphomas

3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas

4 CNS, Neuroblastoma, and Renal Tumors

4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors

5 Sarcomas and Other Solid Tumors

5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors

6 Hematologic Disorders

6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure

7 Pathophysiology, Genetics, and Diagnostics

7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis

8 Clinical Trials and Professional Performance

8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education

9 Chemotherapy and Biotherapy

9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy

10 Immunotherapy, Cellular Therapy, and Radiation

10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam

11 HSCT, Surgery, Transfusion, and Coagulation Therapy

11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy

12 Neurologic, Respiratory, and Cardiovascular Effects

12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects

13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects

13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects

14 Endocrine, Hematologic, Immunologic, and Sensory Effects

14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects

15 Pain, Sleep, Fatigue, and Mental Health

15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects

16 Supportive Care

16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care

17 Infectious and Gastrointestinal Emergencies

17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction

18 Metabolic Emergencies

18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome

19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome

19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)

20 Sickle Cell and Hemostasis Emergencies

20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed

21 Cardiopulmonary Emergencies

21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias

22 Neurologic and Infusion Emergencies

22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation

23 Family, Caregivers, and Social Integration

23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment

24 Development, Grief, Culture, and Community Resources

24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources

9.2 Safe Handling, Administration, and Vesicant Precautions

Key Takeaways Explain This Topic AI

USP <800> governs hazardous drugs from receipt and negative-pressure storage through compounding in a C-PEC inside a C-SEC, administration, disposal, and spills.

Parenteral antineoplastic administration requires chemo-tested gloves (typically two pairs), a chemo-resistant gown, eye protection when splash is possible, a respirator when inhalation risk exists, and a closed-system transfer device when the dosage form allows.

Two nurses independently verify patient, drug, dose (including BSA or weight calculation), route, rate, and time before hanging chemotherapy.

Vesicants such as anthracyclines, vinca alkaloids, and mechlorethamine are given through a functional central line whenever policy allows; if extravasation is suspected, stop, aspirate, do not flush, and notify—there is no single universal antidote.

Home oral hazardous drugs require gloves, no careless crushing, and take-back of unused doses; many centers use about 48 hours of body-fluid precautions after chemotherapy as institutional practice, and pregnant staff should have alternative-duty protections.

Last updated: August 2026

USP <800> is the United States Pharmacopeia chapter that governs hazardous drugs (HDs) from the loading dock to the trash. The National Institute for Occupational Safety and Health (NIOSH) identifies which agents are hazardous; USP <800> tells you how to receive, store, compound, administer, dispose, and clean them. CPHON items mix <800> with vesicant policy and home oral-chemo teaching. The dedicated extravasation-emergency section later in this guide covers antidote algorithms in depth; this section is prevention and the first five minutes .

USP <800> chain: receipt through spills

Receipt. HDs arrive in a designated area. Cartons can be contaminated on the outside. Wear chemo-tested gloves to unpack. A damaged package is a spill until proven otherwise.

Storage. Antineoplastic HDs that require manipulation are stored separately from non-HDs, in a negative-pressure room with adequate air changes. They are not stored in a positive-pressure cleanroom that would blow contamination outward.

Compounding. Sterile HDs are compounded in a containment primary engineering control (C-PEC) —a biological safety cabinet or compounding aseptic containment isolator—inside a containment secondary engineering control (C-SEC) , a negative-pressure room. Horizontal laminar-flow benches that blow toward the operator are wrong for chemotherapy. Closed-system transfer devices (CSTDs) are used during compounding when the dosage form allows ; they supplement the hood, they do not replace it.

Administration. CSTDs are used at the bedside when the dosage form allows . PPE is not optional because you "only spike the bag."

Disposal. Trace chemotherapy (empty bags, tubing, gloves, gowns) goes in designated HD waste. Bulk unused drug follows hazardous-waste rules. Needles are not recapped into a tray of clean syringes.

Spills. Every unit that hangs chemotherapy has a spill kit and staff who have practiced it. Evacuate nonessential people, don full spill PPE (including eye protection and a respirator when the kit or policy requires it), contain, absorb, clean per the kit, and document. A toddler's disconnected tubing on the floor is a spill, not a housekeeping ticket.

PPE for administration

USP <800> and Oncology Nursing Society / Association of Pediatric Hematology/Oncology Nurses practice align on the administration minimum for parenteral antineoplastics:

Two pairs of chemotherapy-tested gloves (change when torn, contaminated, or at policy intervals).

A gown shown to resist HD permeability , closed in the back, long sleeves, cuffs.

Eye and face protection when splash is possible (spiking, disconnects, emesis, splatters).

A respirator (N95 or better per policy) when there is inhalation risk: aerosols, powder, certain spills. A surgical mask is not a respirator.

Do not eat, drink, or apply cosmetics in HD areas. Remove PPE so the outer gloves come off without smearing drug onto skin, then wash hands.

Pregnancy and staff protection. Hazardous-drug handling is a reproductive-risk job. Many institutions offer alternative duty to workers who are pregnant, trying to conceive, or breastfeeding so they are not compounding or administering antineoplastic HDs. This is an occupational-health process, not a suggestion that one glove is enough if you are careful. Male staff also receive reproductive-risk counseling. Medical surveillance programs exist in <800> facilities.

Two-nurse independent verification

Before any parenteral chemotherapy—and for high-alert oral doses per policy—two nurses independently verify:

Patient (two identifiers).

Drug (generic name matches the protocol order).

Dose (recalculate from current height and weight to BSA or mg/kg, including caps).

Route (IV versus IT versus intramuscular versus oral—this is how vincristine deaths are prevented).

Rate .

Time (right day on the roadmap, leucovorin clock running, hydration infusing).

Independent means two people each do the math, not one nurse reading numbers while the other nods. Special IT timeout: preservative-free, IT label, no vinca on the field.

Vesicants versus irritants

Vesicants cause blistering and necrosis if they leak into tissue. Pediatric exemplars include anthracyclines (doxorubicin, daunorubicin), vinca alkaloids (vincristine), mechlorethamine , and others such as dactinomycin. Irritants cause pain or inflammation without the same necrotic punch; many platinum and alkylator infusions sit in this group. Policy—not convenience—decides central versus peripheral . Vesicants are given through a central line whenever one is available and functional (blood return, no occlusion). Peripheral vesicant administration, when a protocol or emergency forces it, uses a freshly started large-vein IV, continuous blood-return checks, and a nurse who stays with the child. Do not hide a vesicant behind an infusion-pump alarm and walk away.

Prevention: confirm blood return before and during, never ignore pain, burning, or swelling, never flush against resistance, use CSTDs, and teach a child old enough to report "it burns."

Drug examples Typical classification Preferred access Immediate leak response concept

Doxorubicin, daunorubicin Vesicant Central when available Stop, aspirate, do not flush; cold compress commonly; dexrazoxane or DMSO are class concepts, not a universal cream

Vincristine Vesicant Central when available Stop, aspirate, do not flush; warm compress commonly; hyaluronidase is the vinca concept

Mechlorethamine Vesicant Central when available Stop, aspirate, notify; follow protocol antidote—not a one-drug-fits-all kit

Many platinum / alkylator infusions Irritant (confirm your policy) Central or carefully monitored peripheral Stop and assess; still notify; do not assume "irritant" means ignore swelling

Extravasation: first steps only

If you suspect extravasation:

Stop the infusion immediately.

Aspirate residual drug through the existing catheter if you can; do not flush .

Disconnect the tubing; leave or remove the catheter per protocol after aspiration.

Notify the provider and mark or photograph the site; elevate the limb.

Apply cold or warm compresses by drug class per protocol (commonly cold for anthracyclines, warm for vincas)—do not invent a single compress rule for every drug.

Antidotes are class-specific , not universal. High-level concepts: dexrazoxane (systemic) and, in some protocols, topical dimethyl sulfoxide (DMSO) for anthracyclines; hyaluronidase for vinca alkaloids. There is no single universal extravasation antidote . Full emergency staging lives in the later hypersensitivity and extravasation chapter.

Oral chemotherapy at home and body fluids

Families handle mercaptopurine , methotrexate , cyclophosphamide , and other orals. Teaching:

Wear gloves . Do not crush hazardous tablets carelessly (aerosol and residue). If a liquid or crush is required, pharmacy should prepare it as an HD.

Store away from food and from siblings' vitamins; never in a labeled candy cup.

Return unused doses to a take-back program—do not flush or toss in regular trash.

Pregnant caregivers should not handle crushed or split HD tablets.

Body-fluid precautions. Many pediatric centers teach families to treat urine, stool, vomit, and diapers as contaminated for about 48 hours after chemotherapy (double-flush, gloves for diapers, lined trash). Teach this as common institutional practice , not as an ONCC-published hour. Follow your unit's number if it differs, but do not leave families with zero precautions.

The CPHON product at the bedside is a nurse in the right PPE, a second nurse who recalculated the BSA, a central line with blood return before a vesicant, and a family that can glove, not crush, and return leftover tablets.

Loading diagram... Hazardous-drug chain and extravasation first steps